Tara S. Abraham
Obstetrics and Gynecology
3301 New Mexico Avenue Northwest, Suite 252
Suite 252
Washington, DC 20016
Suite 252
Washington, DC 20016
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Split tolerance permits safe Ad5-GUCY2C-PADRE vaccine-induced T-cell responses in colon cancer patients.
Journal: Journal for immunotherapy of cancer
Published: December 21, 2018
TCR Retrogenic Mice as a Model To Map Self-Tolerance Mechanisms to the Cancer Mucosa Antigen GUCY2C.
TCR Retrogenic Mice as a Model To Map Self-Tolerance Mechanisms to the Cancer Mucosa Antigen GUCY2C.
Journal: Journal of immunology (Baltimore, Md. : 1950)
Published: August 30, 2018
The swinging pendulum of cancer immunotherapy personalization.
Journal: Personalized medicine
Published: May 17, 2018
Human GUCY2C-Targeted Chimeric Antigen Receptor (CAR)-Expressing T Cells Eliminate Colorectal Cancer Metastases.
Journal: Cancer immunology research
Published: December 07, 2016
One-Health: a Safe, Efficient, Dual-Use Vaccine for Humans and Animals against Middle East Respiratory Syndrome Coronavirus and Rabies Virus.
Journal: Journal of virology
Published: October 14, 2016
Corrigendum: A novel multiple-stage antimalarial agent that inhibits protein synthesis.
Journal: Nature
Published: June 10, 2016
An Evidence-based Approach to the Medical Management of Fibroids: A Systematic Review.
Journal: Clinical obstetrics and gynecology
Published: January 13, 2016
Antimalarial efficacy of MMV390048, an inhibitor of Plasmodium phosphatidylinositol 4-kinase.
Journal: Science translational medicine
Published: December 01, 2015
GUCY2C-directed CAR-T cells oppose colorectal cancer metastases without autoimmunity.
Journal: Oncoimmunology
Published: March 16, 2015
A novel multiple-stage antimalarial agent that inhibits protein synthesis.
Journal: Nature
Published: October 10, 2014
Showing 1-10 of 10
Last Updated: 09/26/2026